185 related articles for article (PubMed ID: 22982653)
21. Epidermal growth factor receptor (EGFR) mutation and p-EGFR expression in resected non-small cell lung cancer.
McMillen E; Ye F; Li G; Wu Y; Yin G; Liu W
Exp Lung Res; 2010 Nov; 36(9):531-7. PubMed ID: 20939760
[TBL] [Abstract][Full Text] [Related]
22. Frequency of EGFR mutations in lung adenocarcinoma with malignant pleural effusion: Implication of cancer biological behaviour regulated by EGFR mutation.
Zou J; Bella AE; Chen Z; Han X; Su C; Lei Y; Luo H
J Int Med Res; 2014 Oct; 42(5):1110-7. PubMed ID: 25239875
[TBL] [Abstract][Full Text] [Related]
23. EGFR mutant-specific immunohistochemistry has high specificity and sensitivity for detecting targeted activating EGFR mutations in lung adenocarcinoma.
Cooper WA; Yu B; Yip PY; Ng CC; Lum T; Farzin M; Trent RJ; Mercorella B; Clarkson A; Kohonen-Corish MR; Horvath LG; Kench JG; McCaughan B; Gill AJ; O'Toole SA
J Clin Pathol; 2013 Sep; 66(9):744-8. PubMed ID: 23757037
[TBL] [Abstract][Full Text] [Related]
24. ERCC1 expression by immunohistochemistry and EGFR mutations in resected non-small cell lung cancer.
Lee KH; Min HS; Han SW; Oh DY; Lee SH; Kim DW; Im SA; Chung DH; Kim YT; Kim TY; Heo DS; Bang YJ; Sung SW; Kim JH
Lung Cancer; 2008 Jun; 60(3):401-7. PubMed ID: 18036700
[TBL] [Abstract][Full Text] [Related]
25. EGFR mutation testing practices within the Asia Pacific region: results of a multicenter diagnostic survey.
Yatabe Y; Kerr KM; Utomo A; Rajadurai P; Tran VK; Du X; Chou TY; Enriquez ML; Lee GK; Iqbal J; Shuangshoti S; Chung JH; Hagiwara K; Liang Z; Normanno N; Park K; Toyooka S; Tsai CM; Waring P; Zhang L; McCormack R; Ratcliffe M; Itoh Y; Sugeno M; Mok T
J Thorac Oncol; 2015 Mar; 10(3):438-45. PubMed ID: 25376513
[TBL] [Abstract][Full Text] [Related]
26. Higher dosage of the epidermal growth factor receptor mutant allele in lung adenocarcinoma correlates with younger age, stage IV at presentation, and poorer survival.
Oakley GJ; Chiosea SI
J Thorac Oncol; 2011 Aug; 6(8):1407-12. PubMed ID: 21587084
[TBL] [Abstract][Full Text] [Related]
27. Dual surrogate markers for rapid prediction of epidermal growth factor receptor mutation status in advanced adenocarcinoma of the lung: A novel approach in resource-limited setting.
Udupa KS; Rajendranath R; Sagar TG; Sundersingh S; Joseph T
Indian J Cancer; 2015; 52(3):266-8. PubMed ID: 26905105
[TBL] [Abstract][Full Text] [Related]
28. Molecular characterization of chronic obstructive pulmonary disease-related non-small cell lung cancer through aberrant methylation and alterations of EGFR signaling.
Suzuki M; Wada H; Yoshino M; Tian L; Shigematsu H; Suzuki H; Alaa M; Tamura H; Fujiwara T; Nagato K; Motohashi S; Moriya Y; Hoshino H; Yoshida S; Shibuya K; Hiroshima K; Nakatani Y; Yoshino I
Ann Surg Oncol; 2010 Mar; 17(3):878-88. PubMed ID: 19841986
[TBL] [Abstract][Full Text] [Related]
29. Detection of epidermal growth factor receptor mutations in serum as a predictor of the response to gefitinib in patients with non-small-cell lung cancer.
Kimura H; Kasahara K; Kawaishi M; Kunitoh H; Tamura T; Holloway B; Nishio K
Clin Cancer Res; 2006 Jul; 12(13):3915-21. PubMed ID: 16818687
[TBL] [Abstract][Full Text] [Related]
30. Detection of epidermal growth factor receptor mutation in transbronchial needle aspirates of non-small cell lung cancer.
Horiike A; Kimura H; Nishio K; Ohyanagi F; Satoh Y; Okumura S; Ishikawa Y; Nakagawa K; Horai T; Nishio M
Chest; 2007 Jun; 131(6):1628-34. PubMed ID: 17565015
[TBL] [Abstract][Full Text] [Related]
31. High concordance of EGFR mutation status between histologic and corresponding cytologic specimens of lung adenocarcinomas.
Sun PL; Jin Y; Kim H; Lee CT; Jheon S; Chung JH
Cancer Cytopathol; 2013 Jun; 121(6):311-9. PubMed ID: 23225576
[TBL] [Abstract][Full Text] [Related]
32. Phase II prospective study of the efficacy of gefitinib for the treatment of stage III/IV non-small cell lung cancer with EGFR mutations, irrespective of previous chemotherapy.
Sunaga N; Tomizawa Y; Yanagitani N; Iijima H; Kaira K; Shimizu K; Tanaka S; Suga T; Hisada T; Ishizuka T; Saito R; Dobashi K; Mori M
Lung Cancer; 2007 Jun; 56(3):383-9. PubMed ID: 17368623
[TBL] [Abstract][Full Text] [Related]
33. EGFR mutation status in tumour-derived DNA from pleural effusion fluid is a practical basis for predicting the response to gefitinib.
Kimura H; Fujiwara Y; Sone T; Kunitoh H; Tamura T; Kasahara K; Nishio K
Br J Cancer; 2006 Nov; 95(10):1390-5. PubMed ID: 17060940
[TBL] [Abstract][Full Text] [Related]
34. An Analysis of EGFR Mutations among 1506 Cases of Non-Small Cell Lung Cancer Patients in Guangxi, China.
Wei WE; Mao NQ; Ning SF; Li JL; Liu HZ; Xie T; Zhong JH; Feng Y; Wei CH; Zhang LT
PLoS One; 2016; 11(12):e0168795. PubMed ID: 27992557
[TBL] [Abstract][Full Text] [Related]
35. Correlation of epithelial-mesenchymal transition markers with clinicopathologic parameters in adenocarcinomas and squamous cell carcinoma of the lung.
Kim SH; Kim JM; Shin MH; Kim CW; Huang SM; Kang DW; Suh KS; Yi ES; Kim KH
Histol Histopathol; 2012 May; 27(5):581-91. PubMed ID: 22419022
[TBL] [Abstract][Full Text] [Related]
36. Detection of epithelial growth factor receptor mutations in cerebrospinal fluid from patients with lung adenocarcinoma suspected of neoplastic meningitis.
Shingyoji M; Kageyama H; Sakaida T; Nakajima T; Matsui Y; Itakura M; Iuchi T; Yokoi S; Kimura H; Iizasa T
J Thorac Oncol; 2011 Jul; 6(7):1215-20. PubMed ID: 21610522
[TBL] [Abstract][Full Text] [Related]
37. [Thyroid transcription factor-1 level is associated with epidermal growth factor receptor mutation status in patients with advanced lung adenocarcinoma].
Niu Y; Wang H; Zhang G; Ma J; Wei B; Ma Z
Zhonghua Jie He He Hu Xi Za Zhi; 2014 Dec; 37(12):919-23. PubMed ID: 25609130
[TBL] [Abstract][Full Text] [Related]
38. Significance of epidermal growth factor receptor gene mutations in squamous cell lung carcinoma.
Miyamae Y; Shimizu K; Hirato J; Araki T; Tanaka K; Ogawa H; Kakegawa S; Sugano M; Nakano T; Mitani Y; Kaira K; Takeyoshi I
Oncol Rep; 2011 Apr; 25(4):921-8. PubMed ID: 21318227
[TBL] [Abstract][Full Text] [Related]
39. [Immunohistochemical detections of EGFR status in NSCLC].
Wang J; Liu C; Zhong D; Xu D; Ning C; Ma Q
Zhongguo Fei Ai Za Zhi; 2015 Apr; 18(4):212-8. PubMed ID: 25936885
[TBL] [Abstract][Full Text] [Related]
40. Epidermal growth factor receptor mutation and p53 overexpression during the multistage progression of small adenocarcinoma of the lung.
Yoo SB; Chung JH; Lee HJ; Lee CT; Jheon S; Sung SW
J Thorac Oncol; 2010 Jul; 5(7):964-9. PubMed ID: 20512074
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
